Status: Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).
Participants needed: 276
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Janssen Research & Development, LLCUpdated: Sep 25, 2026Locations: 16
Eligibility criteria
Have documented initial diagnosis of multiple myeloma according to IMWG diagnost... [+8]
Prior antitumor therapy as follows, in the specified time frame prior to the fir... [+10]